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E-mail address: gborron@um.es (J.C. García-BorrónMelanocortin 1 receptor (MC1R), a Gs protein-coupled receptor expressed in melanocytes, is a major
determinant of skin pigmentation, phototype and cancer risk. MC1R activates cAMP and mitogen-
activated protein kinase ERK1/ERK2 signalling. When expressed in rat pheochromocytoma cell line
cells, the R151C, R160W and D294H MC1R variants associated with melanoma and impaired cAMP
signalling mediated ERK activation and ERK-dependent, agonist-induced neurite outgrowth compa-
rable with wild-type. Dose–response curves for ERK activation and cAMP production indicated
higher sensitivity of the ERK response. Thus, the melanoma-associated MC1R mutations impact dif-
ferently on cAMP and ERK signalling, suggesting that cAMP is not responsible for functional cou-
pling of MC1R to the ERK cascade.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The human melanocortin 1 receptor (MC1R) is a G protein-cou-
pled receptor (GPCR) expressed in epidermal melanocytes [1],
where it regulates the amount and type of melanin pigments pro-
duced. MC1R is a major determinant of skin phototype, sensitivity
to ultraviolet radiation and melanoma and non-melamona skin
cancer risk [2]. Upon stimulation by amelanocyte stimulating hor-
mone (aMSH) or other related proopiomelanocortin-derived pep-
tides expressed in skin cells [3], MC1R triggers cAMP synthesis
leading to activation of the rate-limiting melanogenic enzyme
tyrosinase and increased production of dark, photoprotective
eumelanins [4,5]. MC1R also activates the mitogen-activated pro-
tein kinase (MAPK) module leading to the Ser/Thr kinases ERK1
and ERK2 that control key cellular decisions such as proliferation
or differentiation [6]. The ERK pathway is most often initiated by
binding of growth factors to cell surface tyrosine kinase receptors,
followed by sequential activation of RAS, then members of the RAF
family of kinases, the MAPK kinase MEK and ﬁnally ERK1 and ERK2chemical Societies. Published by E
MC1R, melanocortin 1 recep-
ocyte-stimulating hormone;
tein kinase; PC12, rat pheo-
).[7]. In addition to this classical tyrosine kinase receptor pathway,
the RAS/RAF/MEK/ERK module is also regulated by GPCRs [8,9].
Depending on the cellular context, GPCRs that trigger the cAMP
pathway can either inhibit or activate ERK signalling by partially
understood mechanisms [10]. In most cell types, PKA-dependent
events such as activation of the small GTPase Rap1 or phosphory-
lation of the C-RAF isoform of RAF result in C-RAF inhibition and
lower ERK activity [10]. However, ERK activation by cAMP has been
reported in a few cell types including rat pheochromocytoma cell
line (PC12) cells and mouse melanoma cells [6].
HumanMC1R is extremely polymorphic [1,11] and several rela-
tively frequent alleles are associated with red hair and fair skin (the
red hair colour (RHC) phenotype) and increased risk for melanoma
and other skin cancers [12–14]. Three frequent and penetrant mel-
anoma-associated alleles, R151C, R160W and D294H, are hypo-
morphic variants with reduced functional coupling to the cAMP
cascade [1,15–17]. Since cAMP was reported to trigger ERK activa-
tion in melanocytes [6], signalling to the ERKs might also be im-
paired for these variants. However, this possibility has never
been investigated.
We have analyzed ERK activation by the melanoma-associated
MC1R variants. We show that the R151C, R160W and D294H vari-
ants expressed in PC12 cells activate the ERKs as effectively as
wild-typeMC1R (wtMC1R) in spite of a strong impairment of cAMP
production. We also show that the adenylyl cyclase activator
forskolin increases cAMP levels in human melanoma cells but doeslsevier B.V. All rights reserved.
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Fig. 1. MC1R-mediated ERK activation in melanocytic and heterologous cells. (A)
HBL human melanoma cells were serum-deprived and stimulated with 107 M
NDP-MSH for the times shown. Cell lysates were Western blotted for pERK1/2 and
total ERK2 as loading control. (B) PC12 cells transfected to express wtMC1R were
serum-deprived, stimulated with NDP-MSH and probed for ERK activation. (C)
Agonist-induced cAMP production in HBL and PC12 cells expressing wtMC1R.
**P < 0.005; ***P < 0.0001.
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tives on the functional coupling of MC1R to ERK signalling in
melanocytes.
2. Materials and methods
2.1. Cell culture and transfection
Cell culture reagents were from Gibco BRL-Life Technologies
(Gaithersburg, MD). HBL human melanoma cells were cultured as
described previously [18]. PC12 cells grown in DMEM supple-
mented with 15% fetal bovine serum, 100 U/ml penicillin and
100 lg/ml streptomycin sulphate, were transfected with 0.3 lg
plasmid DNA/well, using Lipofectamine (Invitrogen, Carlsbad,
CA). Expression constructs were prepared in pcDNA3 (Invitrogen)
[17,18].
2.2. Functional assays
Cells grown in 12-well plates were transfected, serum-deprived
for 12–24 h and stimulated as required with the aMSH analogue
norleucine4 D-phenylalanine7-melanocyte-stimulating hormone
[Nle4, D-Phe7] aMSH (NDP-MSH) or nerve growth factor (NGF) (Cal-
biochem, Darmstadt, Germany) at 107 M and 100 ng/ml ﬁnal con-
centrations, respectively, unless stated otherwise. Media were
aspirated and the cells washed with 800 ll ice-cold phosphate buf-
fered saline (PBS), lysed with 200 ll/well 0.1 N HCl preheated at
70 C, and scrapped. The mix was freeze-dried, washed with
100 ll H2O and freeze-dried again. cAMP was measured with a
commercial radioimmunoassay fromAmershamPharmacia Biotech
(Little Chalfont, UK). Parallel dishes were used for protein determi-
nation with bicinchoninic acid. To estimate ERK activation, the lev-
els of phosphorylated ERK (pERK) were analyzed by Western blot.
Cells were solubilized in 75 ll PBS supplemented with PMSF
100 ng/ml, 1% Igepal and 1% phosphatase inhibitor mix from Cal-
biochem. Samples were centrifuged (105 000g, 30 min) and a vol-
ume of supernatant containing 30 lg protein was electrophoresed
and blotted as described [17]. Blots were probed with an anti-
pERK1/2 rabbit polyclonal IgG (Santa Cruz Biotechnology, Santa
Cruz, CA) and stained with a chemiluminescent substrate. Compa-
rable loading was ascertained by stripping and reprobing the mem-
braneswith an anti-ERK2 antibody. Quantiﬁcation of band intensity
was performed with ImageJ (available at www.rsb.info.nih.gov/ij).
3. Results and discussion
3.1. MC1R signalling to ERK in heterologous systems
In order to ﬁnd an appropriate cellular model to study MC1R-
mediated ERK activation, we measured pERK levels and cAMP con-
centrations in HBL human melanoma cells and PC12 cells tran-
siently expressing wtMC1R, following stimulation with NDP-
MSH. HBL cells were selected because they are wild-type for
MC1R [18], N-RAS and B-RAF (our unpublished results) and PC12
cells because they are one of the few cell types where cAMP trig-
gers ERK activation, as reported for melanocytes [6,10,19,20].
ERK1/2 activation was detected by Western blot using an antibody
speciﬁc for the active enzyme phosphorylated at Thr202 and
Tyr204, and cAMP was determined by radioimmunoassay [17]. In
HBL cells, pERK signals increased rapidly and transiently upon
treatment with NDP-MSH, with maximal activation 5 min after
agonist challenge (Fig. 1A). PC12 cells expressing MC1R also
showed an increase in ERK phosphorylation, with maximal values
15 min after stimulation followed by a slower decrease towards
baseline (Fig. 1B). NDP-MSH strongly increased intracellular cAMPin both cell types (Fig. 1C). Accordingly, transient transfection of
PC12 cells was used to compare signalling from wild-type or vari-
ant MC1R to both the cAMP and the ERK pathways, under identical
conditions of cellular setting and receptor expression levels.
3.2. Similar activation of ERKs by wild-type and variant MC1R
The melanoma-associated R151C, R160W and D294H mutants
show diminished ability to stimulate cAMP synthesis in melanocy-
tic cells [1,15–17]. Functional assays in PC12 cells yielded similar
results, conﬁrming that these alleles are hypomorphic variants
(Fig. 2A). D294H was the most severely impaired mutant, consis-
tent with results obtained in other cell types [17,21]. Surprisingly,
ERK activation was equally intense in cells expressing variant or
wtMC1R (Fig. 2B). Moreover, the kinetics of ERK phosphorylation
was also similar for wtMC1R and the RHC variants, with maximal
activation occurring roughly 15 min after agonist challenge. Strip-
ping of membranes and reprobing with an anti-Flag monoclonal
antibody conﬁrmed comparable levels of expression of all MC1R
forms (not shown). The ERK1/2 cascade was not activated by
NDP-MSH in cells transfected with two complete loss-of-function
mutants unable to reach the plasma membrane, L93R and R162P
[1] or with empty vector (not shown), thus conﬁrming the speciﬁc-
ity of the response.
SustainedERKactivation in PC12cells is associatedwith their dif-
ferentiation into sympathetic cells, a process characterized by neu-
rite outgrowth [19,22]. To further demonstrate wtMC1R and RHC
variant signalling to the ERKs, we analyzed NDP-MSH-mediated
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Fig. 2. Efﬁcient signalling of RHC variants to the ERKs. PC12 cells transfected with wtMC1R or the RHC variants R151C, R160W or D294H were challenged with 107 M NDP-
MSH. (A) Kinetics of cAMP generation upon stimulation with 107 M NDP-MSH. For all time points, cAMP increases over untreated controls were statistically signiﬁcant
(P < 0.005) except for the D294H variant, that did not display signiﬁcant responses. (B) Kinetics of ERK activation by wild-type or variant MC1R. Representative blots (left), and
quantiﬁcation of three experiments (means ± S.D., right) are shown. *P < 0.05; **P < 0.005; ***P < 0.0001.
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with NDP-MSH or NGF as a positive control developed neurites
(Fig. 3A). Neurite outgrowthwas dependent on ERK activation since
it was abolished by the MEK inhibitor PD98059. The percentage of
cells developing neurites increased signiﬁcantly upon NDP-MSH
treatment (28 ± 4%, P < 0.005) compared with untreated controls
and was roughly consistent with the transfection efﬁciency, sug-
gesting that most MC1R-expressing cells were responsive. NDP-
MSH failed to induce neurite outgrowth in cells transfected with
empty vector (not shown). Statistically signiﬁcant (P < 0.005) NDP-
MSH-induced neurite outgrowthwas also observed in cells express-
ing the RHC variants. Although the length of the dendritic processes
was similar, the percentage of cells developing neurites was lower
compared with wild-type (Fig. 3B). This smaller efﬁciency might
be relatedwith their impaired cAMP signalling, since cAMPhas been
shown to cooperate with ERK signalling in promoting neuritogene-
sis in PC12 cells [19].
Thus, although the RHC variants showed reduced functional
coupling to the cAMP pathway, they efﬁciently stimulated ERK
activity.
3.3. ERK activation is induced at lower agonist concentration than
cAMP synthesis
Treatment of B16 mouse melanoma cells with aMSH or cAMP
elevating agents has been reported to activate ERK signalling in a
RAS and B-RAF-dependent fashion [6], suggesting that MC1R-
dependent ERK activation in these cells is mediated by cAMP. How-
ever, the differential effect of the RHC mutations on signalling to
cAMP or the ERKs indicated that ERK activation by MC1R might,
in fact, be independent on cAMP production. To further explore
the relationship between cAMP and ERK signalling, we analyzedthe functional coupling of three artiﬁcial variants with altered sig-
nalling to cAMP: E94K, a mutant that signals constitutively to
cAMP in the absence of agonist [18], T308A-S316A and T308D-
S316D, two double mutants where the Thr308 and Ser316 targets
of G protein-coupled receptor kinase 6 are mutated to Ala and Asp,
respectively. These double mutants display a dramatically reduced
functional coupling to cAMP [17]. Moreover, whereas T308A-
S316A is resistant to internalization due to inability to undergo
GRK-dependent phosphorylation, T308D-S316D is constitutively
internalized and associated with endocytic vesicles [17]. As shown
in Fig. 4A, the internalization-resistant T308A-S316A mutant with
impaired signalling to cAMP was as efﬁcient as wtMC1R in trigger-
ing ERK phosphorylation following stimulation with NDP-MSH.
Moreover, neither the constitutively active E94K variant nor the
constitutively internalized T308D-S316D mutant was more potent
than wtMC1R in activating the ERKs. These data suggest that
MC1R-mediated ERK activation is independent on receptor inter-
nalization, and does not involve cAMP synthesis. Consistent with
independence on cAMP, treatment of HBL human melanoma cells
with the potent adenylyl cyclase activator forskolin (10 lM,
15 min) strongly increased intracellular cAMP levels, but failed to
activate the ERKs (Fig. 4B). Conversely, NDP-MSH promoted ERK
phosphorylation while yielding a smaller stimulation of cAMP syn-
thesis. The inability of forskolin to trigger ERK phosphorylation
was conﬁrmed in kinetic experiments where HBL cells were trea-
ted with the drug from 5 to 60 min (not shown).
Since activation of the cAMP and ERK pathways are most likely
independent events, they might display different NDP-MSH dose–
response curves. To check this possibility, PC12 cells expressing
wtMC1R were stimulated with NDP-MSH concentrations from
1012 to 107 M, and pERK and cAMP intracellular levels were
measured. ERK phosphorylation was detectable at concentrations
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Fig. 3. MC1R-dependent neurite outgrowth in PC12 cells. (A) Cells expressing wtMC1R were treated with NDP-MSH (107 M) or NGF (100 ng/ml) for 48 h, with or without
PD98059 (50 lM). (B) Neurite outgrowth in cells expressing variant MC1R. Cells expressing the variants indicated on the left of each row were treated with NDP-MSH or NGF
as indicated. The lower graphs show the percentage of cells developing neurites (left), and the mean length of dendritic processes (right, results shown as means ± S.E.M.).
3272 C. Herraiz et al. / FEBS Letters 583 (2009) 3269–3274as low as 1012 M (Fig. 4C), whereas cAMP increases were only
detected at 1010 M or higher (Fig. 4D). Accordingly, the dose–
response curve for ERK phosphorylation was dramatically left-
shifted by up to 3 logs relative to the cAMP curve. These differencesin dose–response curves suggest that ERK activation might involve
effector(s) with higher afﬁnity for MC1R than the Gs protein
responsible for coupling to cAMP. Experiments aiming at the iden-
tiﬁcation of this effector have excluded the involvement of PKC or
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curves for ERK activation and Gas-dependent activation of cAMP
synthesis (Fig. 4D) argue against involvement of free bc dimers
in triggering ERK phosphorylation, although a role for bc dimers
cannot be formally excluded based on the results reported here. Fi-
nally, data obtained with the T308A-S316A and T308D-S316D mu-
tants also suggest that ERK activation is not related with the
arrestin-dependent formation of endocytic vesicles [8]. Therefore,
the precise mechanisms coupling MC1R activation to ERK phos-
phorylation remain unknown.
In summary, we showed that the frequent melanoma-associ-
ated MC1R variants R151C, R160W and D294H are loss-of-functionforms in signalling to cAMP, but activate the ERKs as efﬁciently as
wild-type. This suggests that coupling of MC1R activation to cAMP
or to ERKs are independent events, and provides a remarkable
example of differential impact of point mutations on two signalling
pathways. Moreover, ERK phosphorylation is triggered at much
lower agonist concentrations than cAMP synthesis, suggesting that
melanocytes might display a graded spectrum of responses to mel-
anocortin ligands of MC1R, with ERK-dependent processes occur-
ring at lower agonist levels than cAMP-dependent events. Finally,
it also suggests that melanocytes harbouring variant MC1R might
display an imbalanced functional response to melanocortins, with
normal signalling to the ERKs but reduced coupling to cAMP.
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